Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects

@article{Shin2017PharmacokineticsAT,
  title={Pharmacokinetics and tolerability of DA-8031, a novel selective serotonin reuptake inhibitor for premature ejaculation in healthy male subjects},
  author={D. Shin and S. Lee and S. Yi and S. Yoon and Joo-Youn Cho and Mi Young Bahng and I. Jang and Kyung-Sang Yu},
  journal={Drug Design, Development and Therapy},
  year={2017},
  volume={11},
  pages={713 - 723}
}
  • D. Shin, S. Lee, +5 authors Kyung-Sang Yu
  • Published 2017
  • Medicine
  • Drug Design, Development and Therapy
  • Objective DA-8031 is a selective serotonin reuptake inhibitor under development for the treatment of premature ejaculation. This is the first-in-human study aimed at evaluating the pharmacokinetics and tolerability of DA-8031 and its metabolites (M1, M2, M4, and M5) in the plasma and urine after administration of a single oral dose in healthy male subjects. Methods A dose block-randomized, double-blind, placebo-controlled, single ascending dose study was conducted. Subjects received either… CONTINUE READING
    5 Citations

    Figures, Tables, and Topics from this paper

    References

    SHOWING 1-10 OF 30 REFERENCES
    Candidate molecule for premature ejaculation, DA-8031: in vivo and in vitro characterization of DA-8031.
    • 17
    Clinically Relevant Pharmacology of Selective Serotonin Reuptake Inhibitors
    • S. Preskorn
    • Biology, Medicine
    • Clinical pharmacokinetics
    • 1997
    • 342
    • Highly Influential
    Effect of Cytochrome P450 polymorphism on the action and metabolism of selective serotonin reuptake inhibitors
    • 24
    • Highly Influential
    On-demand SSRI treatment of premature ejaculation: pharmacodynamic limitations for relevant ejaculation delay and consequent solutions.
    • 88
    Meta-analysis of selective serotonin reuptake inhibitor-associated QTc prolongation.
    • 118
    • PDF
    QT-interval prolongation by non-cardiac drugs: lessons to be learned from recent experience
    • 226
    Reduced verapamil clearance during long‐term oral administration
    • 126